<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Bevacizumab; Osteonecrosis of the jaw" /><meta name="IX" content="Bevacizumab; Osteonecrosis of the jaw" /><title>Bevacizumab: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5433-bevacizumab.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5433-bevacizumab.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="PHP5433-bevacizumab.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5180-cytotoxic-drugs.htm">8.1 Cytotoxic drugs</a> &gt; <a href="PHP5425-other-antineoplastic-drugs.htm">8.1.5 Other antineoplastic drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5431-arsenic-trioxide.htm" title="Previous: ARSENIC TRIOXIDE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5436-bevacizumab.htm" title="Next: BEVACIZUMAB">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a304008.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bevacizumab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/20782-d.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Bevacizumab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: B &gt; Interactions of Bevacizumab</p></div></li></ul><ul><li><h3>British National Formulary (5)</h3></li><li><a href="PHP4653-bisphosphonates.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bisphosphonates</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 6 Endocrine system &gt; 6.6 Drugs affecting bone metabolism &gt; 6.6.2 Bisphosphonates and other drugs affecting bone metabolism</p></div></li><li><a href="PHP5436-bevacizumab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">BEVACIZUMAB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Bevacizumab</p></div></li><li><a href="PHP5437-avastin.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Avastin®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Bevacizumab &gt; BEVACIZUMAB</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22bevacizumab%22%22osteonecrosis+of+the+jaw%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (5)</a></li></ul><ul><li><h3>BNF for Children</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13464-bisphosphonates.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">6.6.2 Bisphosphonates</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 6 Endocrine system &gt; 6.6 Drugs affecting bone metabolism</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/20782-d.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bevacizumab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/01191.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bevacizumab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; B &gt; BE</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-B35.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bevacizumab</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; B</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E4E3E0R0D931.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Bevacizumab</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; B</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><?highlighter on?><h1>Bevacizumab</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p><strong>Bevacizumab</strong> is a monoclonal antibody that inhibits vascular endothelial growth factor. It is licensed for the treatment of metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy (but see NICE guidance below). It is also licensed for first-line treatment of metastatic breast cancer in combination with paclitaxel, or with capecitabine when treatment with other chemotherapy, including taxanes or anthracyclines is not appropriate; patients who have received adjuvant taxane or anthracyline-containing regimens in the previous 12 months should not be treated with bevacizumab in combination with capecitabine. Bevacizumab is also licensed for advanced or metastatic renal cell carcinoma in combination with interferon alfa-2a (but see <a title="BNF:target-block: Bevacizumab nice guidance" href="PHP5514-protein-kinase-inhibitors.htm#PHP5525">NICE Guidance</a>). Bevacizumab, in combination with platinum-based chemotherapy, is licensed for first-line treatment of unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. It is also licensed, in combination with carboplatin and paclitaxel, for the first-line treatment of advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer and, in combination with carboplatin and gemcitabine, for first recurrence of platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have not been treated previously with bevacizumab or other drugs that target vascular endothelial growth factor. Bevacizumab is given by intravenous infusion.</p><div id="PHP5434" class="cI"><p class="cAE">MHRA/CHM advice</p><h3 class="cT">Bevacizumab and sunitinib: risk of osteonecrosis of the jaw (January 2011)</h3><p>Treatment with bevacizumab or sunitinib may be a risk factor for the development of osteonecrosis of the jaw.</p><p>Patients treated with bevacizumab or sunitinib, who have previously received bisphosphonates, or are treated concurrently with bisphosphonates, may be particularly at risk.</p><p>Dental examination and appropriate preventive dentistry should be considered before treatment with bevacizumab or sunitinib.</p><p>If possible, invasive dental procedures should be avoided in patients treated with bevacizumab or sunitinib who have previously received, or who are currently receiving, intravenous bisphosphonates.</p></div><p>The <a title="NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (April 2012) that bevacizumab (<em>Avastin</em>®) is <strong>not</strong> recommended for use within NHS Scotland for the the first-line treatment of patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or (September 2012), in combination with carboplatin and paclitaxel, for the first-line treatment of advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.</p><div id="PHP5435" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (January 2007)</h3><p>Bevacizumab in combination with fluorouracil plus folinic acid, with or without irinotecan, is <strong>not</strong> recommended for the first-line treatment of metastatic colorectal cancer; see also NICE guidance <a title="Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012) NICE guidance" href="PHP5450-cetuximab.htm#PHP18395">Cetuximab, bevacizumab and panitimumab for the treatment of metastatic colorectal cancer after first-line chemotherapy</a>.</p><p><a href="http://www.nice.org.uk/TA118">www.nice.org.uk/TA118</a></p></div><div id="PHP19182" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010)</h3><p>Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine is <strong>not</strong> recommended for the treatment of metastatic colorectal cancer.</p><p><a href="http://www.nice.org.uk/TA212">www.nice.org.uk/TA212</a></p></div><div id="PHP19183" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (February 2011)</h3><p>Bevacizumab in combination with a taxane is <strong>not</strong> recommended for the first-line treatment of metastatic breast cancer.</p><p><a href="http://www.nice.org.uk/TA214">www.nice.org.uk/TA214</a></p></div><div id="PHP18629" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (August 2012)</h3><p>Bevacizumab in combinations with capecitabine is <strong>not</strong> recommended within its marketing authorisation for the first-line treatment of metastatic breast cancer, that is, when treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or when taxanes or anthracyclines have been used as part of adjuvant treatment in the previous 12 months.</p><p><a href="http://www.nice.org.uk/TA263">www.nice.org.uk/TA263</a></p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP5436-bevacizumab"><a href="PHP5436-bevacizumab.htm" title="BEVACIZUMAB">BEVACIZUMAB</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5431-arsenic-trioxide.htm">Previous: ARSENIC TRIOXIDE</a> | <a class="top" href="PHP5433-bevacizumab.htm#">Top</a> | <a accesskey="]" href="PHP5436-bevacizumab.htm">Next: BEVACIZUMAB</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>